Welcome to our dedicated page for Purple Biotech news (Ticker: PPBT), a resource for investors and traders seeking the latest updates and insights on Purple Biotech stock.
Purple Biotech Ltd. (PPBT) generates frequent news as a clinical-stage oncology company developing therapies that, according to its own reports, target tumor immune evasion and drug resistance. Investors and observers following PPBT news can track updates on its CAPTN-3 tri-specific antibody platform, the CEACAM1-blocking antibody CM24, and the dual IRS1/2 and STAT3 inhibitor NT219, as well as financing and listing developments.
Recent press releases highlight CAPTN-3 as a key source of news. The company has announced manufacturing milestones for IM1240, the first tri-specific antibody from the platform targeting 5T4, CD3 and NKG2A, including achievement of a commercially viable yield. Additional updates describe non-human primate toxicology data for IM1240, with Purple Biotech reporting an expanded therapeutic window compared with a non-capped comparator and a pharmacokinetic profile characterized by increased systemic exposure and prolonged half-life in that study.
News flow also covers preclinical data presentations at scientific meetings such as the ESMO Immuno-Oncology Congress and other conferences. These releases describe anti-tumor activity of IM1240 and IM1305 in models resistant to prior PD-1 therapy, transcriptomic analyses supporting the inclusion of an NKG2A arm, and ex vivo results in patient-derived tumor biopsies. Such items provide context on how the company positions CAPTN-3 within immuno-oncology research.
Beyond CAPTN-3, Purple Biotech issues updates on CM24 Phase 2 data in pancreatic ductal adenocarcinoma and on NT219, including an intention to grant a European patent for NT219 combination regimens and progress of a Phase 2 study in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Financial and corporate news includes quarterly results, public offerings of American Depositary Shares and warrants, at-the-market offering agreements, and Nasdaq minimum bid price notifications.
Readers who monitor PPBT news can use this page to follow scientific milestones, regulatory and clinical progress, capital-raising transactions, and listing-related announcements directly sourced from company press releases and SEC-furnished documents.
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) has initiated a Phase 1b/2 clinical trial for its monoclonal antibody CM24, aimed at treating advanced cancer patients. This trial, conducted in collaboration with Bristol Myers Squibb, will focus on non-small cell lung cancer (NSCLC) and pancreatic cancer. Preliminary results are expected in the second half of 2021. CM24 demonstrated a 33% disease control rate in previous studies, showing promise in targeting CEACAM1, a key immune checkpoint protein.
Purple Biotech, trading under the ticker PPBT on NASDAQ/TASE, has announced the presentation of new preclinical data on NT219, a dual inhibitor targeting IRS1/2 and STAT3. This data will be showcased at the AACR 2021 Annual Meeting from April 10-15 and May 17-21. The study highlights the significant role of IRS2 in colorectal cancer brain metastasis and suggests NT219’s potential in addressing this issue. Ongoing trials for NT219 as a treatment for solid tumors aim to deliver top-line data by late 2021.
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) appointed Robert Gagnon to its Board of Directors, bringing 15 years of corporate finance expertise, primarily in biotech. Gagnon will serve until the 2022 annual general meeting. His appointment aims to leverage his experience as the company approaches key clinical milestones for anti-cancer therapies CM24 and NT219. Gagnon, currently Chief Business and Financial Officer at Verastem Oncology, has held significant financial roles at several biotech firms. This leadership change may enhance strategic direction and drive shareholder value.
Purple Biotech (PPBT) announced significant advancements in its anti-cancer therapies and financial results for 2020. Key highlights include the completion of patient recruitment for the NT219 clinical trial and imminent Phase 1b/2 studies for CM24. The company raised $68.5 million in 2020, ending with $60.8 million in cash, sufficient to support operations until 2024. Despite increased R&D expenses leading to a higher operating loss of $12.6 million, cash resources appear robust, supporting ongoing clinical initiatives aimed at improving cancer treatment outcomes.